Parents sue Paxil maker for heart defects
Five more suits have been filed in Pennsylvania against the makers of the antidepressant Paxil on behalf of children who have developed severe heart problems.
News by Scott Thomas
ACOG Issues Opinion on SSRI Antidepressant Use During Pregnancy
Washington, DC — The use of selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors for the treatment of depression during pregnancy should be individualized based on their respective risks and benefits, according to a new Committee Opinion issued by The American College of Obstetricians and Gynecologists’ (ACOG) Committee on Obstetric Practice. The Committee also advised that a particular SSRI medication known as paroxetine (Paxil®) be avoided, when possible, by pregnant women or women planning to become pregnant due to the potential risk of fetal heart defects, newborn persistent pulmonary hypertension, and other negative effects.
Ob/Gyn Group Urges Pregnant Women to Shun Paxil
A group representing America’s obstetricians is recommending that women avoid the antidepressant Paxil if they are pregnant or planning on becoming pregnant, due to a potential heightened risk for birth defects.
First Paxil birth defect lawsuit filed
The parents of 2-year-old Eric Jackson have filed the first lawsuit claiming that use of the antidepressant Paxil during pregnancy caused birth defects in their won.
Blood pressure pill doubles risk of birth defects
Some blood pressure drugs previously thought to be safe when taken early in pregnancy now appear to substantially raise the risk of major birth defects, doctors say.
Paxil Maker Sued Over Child Born with Severe Birth Defects
The parents of a two-year old boy have filed a lawsuit against the maker of Paxil, alleging that the mother’s use of the antidepressant during pregnancy cause her son to be born with severe heart defects.
Treatment Challenges of Depression in Pregnancy and the Possibility of Persistent Pulmonary Hypertension in Newborns
Decisions about how to treat depression in pregnant women are increasingly complex. Patients and physicians must carefully consider and discuss together the potential benefits and risks of treatment with antidepressants during pregnancy. Two new studies provide important information to be considered in making such decisions. The studies included women who had been treated with antidepressant drugs that act as selective serotonin reuptake inhibitors (SSRIs) or, in a few cases, other antidepressants. SSRI medications are the most commonly used drugs to treat depression in the U.S.
Updated Product Labeling Warns of Birth Defect
The U.S. Food and Drug Administration (FDA) recently announced that early research studies with the drug Paxil (paroxetine) suggest that taking the drug during the first three months of pregnancy may increase a woman’s risk of having a baby with birth defects, particularly heart defects.
FDA Advising of Risk of Birth Defects with Paxil
The Food and Drug Administration today is alerting health care professionals and patients about early results of new studies for Paxil (paroxetine) suggesting that the drug increases the risk for birth defects, particularly heart defects, when women take it during the first three months of pregnancy. Paxil is approved for the treatment of depression and several other psychiatric disorders. FDA is currently gathering additional data and waiting for the final results of the recent studies in order to better understand the higher risk for birth defects that has been seen with Paxil.
FDA strengthens pregnancy warning on Glaxo’s Paxil
The Food and Drug Administration said Thursday that the warning label on GlaxoSmithKline’s widely-prescribed anxiety drug Paxil has again been revised to advise the drug may cause heart defects in babies.